What is Insulet's market cap?

Insulet (PODD) has a market capitalization of $11.4B and trades on NASDAQ.

What is Insulet's revenue and profitability?

Insulet generated $2.9B in trailing twelve-month revenue with net income of $302.8M, representing a net margin of 10.4%. Gross margin stands at 71.0%, with free cash flow of $415.7M. These figures are based on the Q1 2026 filing.

Who are Insulet's competitors?

Insulet's key competitors include Tandem Diabetes Care, Inc., Embecta Corp., Medtronic plc, and others. These companies compete in similar markets and product categories.

Who does Insulet partner with?

Insulet's notable partners include Amgen, Dexcom, Inc., Abbott Diabetes Care, Inc., and others.

Where is Insulet headquartered?

Insulet is headquartered in United States of America and employs approximately 3,000 people. It has been publicly traded since 2007.

Insulet

PODD

Insulet Corporation is a medical device company specializing in the development and commercialization of the Omnipod platform, a proprietary tubeless insulin delivery system.

Market cap

$11.43B-45.6%

Revenue$2.9B+31.9%

Net income$302.8M-24.7%

Free cash flow$415.7M+42.7%

EPS (diluted)$4.29-22.7%

Trailing twelve months · change vs. prior year

Table of contents

Earnings

Q1 2026 report

May 6, 2026

Revenue$761.7MBeat by $31.8M EPS$1.42Beat by $0.23

Read the full report

Next report

Aug 5, 2026 (In 1 week)

Revenue estimate$787.4M

EPS estimate$1.45

Financials

Q1 2026

Income statement

See full

Revenue$761.7M+33.9%

Gross profit$529.0M+29.3%

Operating income$122.1M+37.5%

Net income$91.1M+157%

EPS (diluted)$1.30+160%

Balance sheet

See full

Cash & equivalents$480.4M-62.6%

Total debt$969.7M-45.5%

Total equity$1.3B-2.1%

Total assets$3.0B-15.1%

Cash flow

See full

Operating cash flow$113.8M+78.4%

CapEx$24.3M+97.6%

Free cash flow$89.5M+73.8%

Valuation & ratios

Valuation

See full

Market cap$11.43B-45.6%

Enterprise value$11.92B-44.1%

P/E37.7×-49.4×

P/S3.9×-4.8×

Profitability

See full

Gross margin71%+0.6pp

Operating margin17.5%+2.0pp

Net margin10.4%-7.9pp

FCF margin14.3%+1.1pp

Returns & leverage

See full

Return on equity23%-14.9pp

Debt / equity0.7×-0.6×

Current ratio2.5×-2.0×

Segments

By product

See full

Total Omnipod products$758.4M+36.9%

International$242.9M+59.5%

Drug Delivery$3.3M-77.9%

Competitors

By market cap

Eli Lilly$1.07T+47.2%

Medtronic$107.81B-8.5%

Insulet$11.4B-44.4%

Tandem Diabetes Care$1.2B+4.9%

Beta Bionics, Inc.$712.5M+17.5%

Embecta Corp.$203.8M-69.2%

Oramed Pharmaceuticals$170.3M+88.6%

Modular Medical$12.5M-67.1%

By revenue growth

Beta Bionics, Inc.+57.9%

Eli Lilly+47.4%

Insulet+31.9%

Medtronic+8.4%

Tandem Diabetes Care+4.5%

Embecta Corp.-3.4%

By net margin

Eli Lilly34.99%+12.3pp

Medtronic13.2%-0.7pp

Embecta Corp.10.73%+5.8pp

Insulet10.44%-7.9pp

Tandem Diabetes Care-9.2%+9.5pp

Beta Bionics, Inc.-60.27%+41.4pp

Profile

Insulet Corporation is a medical device company specializing in the development and commercialization of the Omnipod platform, a proprietary tubeless insulin delivery system. The company's core value proposition is simplifying life for people with insulin-dependent diabetes through automated, wearable technology that eliminates the need for traditional insulin pumps with tubing or multiple daily injections. Beyond diabetes care, the company leverages its pod technology for the delivery of other non-insulin subcutaneous drugs.

Competitive position

A leading provider of tubeless insulin pump technology with a strong focus on automated insulin delivery and pharmacy-channel distribution.

GeographiesUnited States, Europe, Australia, Canada, Middle East

Customer segmentsPatients, Healthcare Systems, Wholesalers, Pharmaceutical Manufacturers

Business modelRazor-razorblade model, Direct-to-consumer, B2B distribution

SuppliersApplication-specific integrated circuit (ASIC) suppliers, Bluetooth low-energy chip manufacturers, Contract manufacturers, Raw material suppliers

CustomersWholesale distributors, Retail pharmacies, Hospitals and healthcare organizations, Direct-to-consumer patients

CountryUnited States of America

Listed2007

Employees3.0K

CEOAshley McEvoy

SectorHealthcare

IndustryMedical - Devices

Websiteinsulet.com

FilingsSEC EDGAR

Ask your AI about Insulet.

Connect your AI assistant and dig into the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Insulet's market cap?: Insulet (PODD) has a market capitalization of $11.4B and trades on NASDAQ.
What is Insulet's revenue and profitability?: Insulet generated $2.9B in trailing twelve-month revenue with net income of $302.8M, representing a net margin of 10.4%. Gross margin stands at 71.0%, with free cash flow of $415.7M. These figures are based on the Q1 2026 filing.
Who are Insulet's competitors?: Insulet's key competitors include Tandem Diabetes Care, Inc., Embecta Corp., Medtronic plc, and others. These companies compete in similar markets and product categories.
Who does Insulet partner with?: Insulet's notable partners include Amgen, Dexcom, Inc., Abbott Diabetes Care, Inc., and others.
Where is Insulet headquartered?: Insulet is headquartered in United States of America and employs approximately 3,000 people. It has been publicly traded since 2007.